On Friday, August 22, Welcure Drugs & Pharmaceuticals Ltd. gave investors three pieces of excellent news. The board has authorized a 1:10 bonus issue, which will give existing shareholders free shares, and a 1:10 stock split, making shares more affordable for retail investors.
The corporation also intends to increase its authorized share capital to Rs 196 crore.
By combining a capital expansion, bonus issue, and stock split, Welcure has solidified its position as a market observer. The aforementioned disclosures were made after market hours, and Welcure Drugs closed at a 5% lower circuit limit at Rs 11.92 per share during the closing session, with a market valuation of Rs 134.11 Cr.
“These proposals are being considered with the objective of enhancing liquidity, broadbasing shareholding and improving affordability for investors, subject to the Board’s decision and subsequent statutory/ shareholder approvals,” said Welcure Drugs & Pharmaceuticals.
Welcure Drugs & Pharmaceuticals Stock Split
“The Board has considered and approved Sub-division/ split of the existing Equity Shares of the Company, such that each Equity Share having face value of Rs. 10/- (Rupees Ten only) each fully paid-up, be sub-divided/split into such number of Equity Shares having face value of Rs. 1 each fully paid-up, subject to the approval of Equity Shareholders of the Company through Postal Ballot. The Record Date for sub-division/split of existing Equity Shares shall be decided after taking aforesaid approval of the Equity Shareholders of the Company,” said the company in a stock exchange filing on Friday.
The details state that, subject to shareholder approval through a postal ballot, the subscribed and paid-up share capital of Rs 112.35 crore will be divided into 112.35 crore fully paid-up shares of Re.1 each, while the authorized share capital of Rs 186 crore will now be divided into 186 crore fully paid-up shares of Re.1 each.
The Board has considered & approved the increase in the authorized share capital of Welcure Drugs & Pharmaceuticals from Rs. 186,00,00,000/- to Rs. 196,00,00,000/- subject to the approval of the members.
Welcure Drugs & Pharmaceuticals Bonus Shares
“The Board has considered and approved issue of Bonus Shares in the ratio of 1:10 (One bonus equity shares for every Ten equity share) to the eligible equity shareholders of the Company as on the proposed record date by capitalization of securities premium, subject to the approval of the shareholders of the Company,” Welcure Drugs & Pharmaceuticals confirmed in a BSE filing on Friday.
For every ten existing shares held as of the record date, Welcure Drugs & Pharmaceuticals Ltd. has approved a bonus issue in the ratio of 1:10, awarding one additional fully paid-up equity share of Rs 10 apiece. Subject to shareholder approval, a total of about 1,12,35,820 bonus shares, valued at approximately Rs 11.23 crore, would be issued. The funds will come from the company’s retained earnings, free reserves, and securities premium.
The paid-up share capital would increase from Rs 112.35 crore, which includes 11.23 crore shares, to Rs 123.59 crore, which includes 12.35 crore shares, after the bonus issuance. In order to ensure enough support for the bonus issuance, the company has set aside Rs 11.23 crore from reserves for this reason. As of June 30, 2025, it had free reserves of Rs 13.37 crore.
Welcure Drugs Announces New Rs 70-80 Crore Research Project and Board Meeting to Consider Fund-Raising
Welcure Drugs & Pharmaceuticals Ltd. said on August 20, 2025, that it will set up an Agro-Pharma Research Laboratory to transform botanical and agricultural ingredients into pharmaceutical-grade goods. In order to enter foreign markets, the firm aims to bring its facilities into compliance with cGMP guidelines and the U.S. Food and Drug Administration’s guidelines for the manufacturing of botanical drugs.
This project is expected to cost between Rs 70 and Rs 80 crore, which includes costs for quality systems, pilot lines, and infrastructure. Through a Qualified Institutional Placement (QIP), the company aims to raise up to Rs 80 crore to finance this project. On August 28, 2025, the Board of Directors will meet to discuss and possibly approve the QIP.
Welcure Drugs Target Price
“Welcure Drugs is finding support near ₹11.50 after a mild correction. Sustaining above this zone could trigger a bounce toward ₹13-₹14 in the short term. Momentum indicators hint at base formation at lower levels. A decisive breakout above ₹14 would strengthen the bullish outlook, while ₹11 should be kept as a strict stop-loss,” commented Riyank Arora, technical analyst at Mehta Equities Ltd.